Molecular docking studies of kirenol a traditional Chinese medicinal compound against rheumatoid arthritis cytokine drug targets (TNF-α, IL-1 and IL-6).

被引:0
作者
Wu, Jing [1 ]
Qu, Yuan [1 ]
Deng, Jia-xin [1 ]
Liang, Wan-yi [1 ]
Jiang, Zhen-lan [1 ]
Lai, Rong [1 ]
Yu, Qing-hong [1 ]
机构
[1] Southern Med Univ, ZhuJiang Hosp, Dept Rheumatol & Clin Immunol, Guangzhou 510282, Guangdong, Peoples R China
来源
BIOMEDICAL RESEARCH-INDIA | 2017年 / 28卷 / 05期
关键词
Rheumatoid arthritis; TNF-alpha; IL-1; IL-6; Kirenol; Molecular docking; INTERLEUKIN-6; DISEASE;
D O I
暂无
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Rheumatoid Arthritis (RA) an autoimmune multifactorial disease impairing the quality of life of the diseased is a challenging prospect in terms of treatment. The disease has been treated from ancient times and from their wisdom, we have taken one traditional Chinese medicinal compound named kirenol. The compound is from herbal extract of Herba Siegesbeckiae and in this study we are exploring its inhibiting potential of cytokine target i. e. TNF-alpha, IL-1 and IL-6 using Auto Dock tool. In our study we have used Auto Dock 4.2 an Insilico tool to check the effect of the kirenol on three important cytokine target i. e. TNF-alpha, IL-1 and IL-6. The molecular docking approach using AutoDock 4.2 tool with default parameters was used to calculate the binding energies. All the three cytokines showed spontaneous binding with kirenol, varying from a Delta G range of -6.75 to -2.68 Kcal/mole. The results generated showed IL-6 to be the best target for kirenol. Both, its binding energy and number of interactions is higher when compared to that of other two.
引用
收藏
页码:1992 / 1995
页数:4
相关论文
共 24 条
[1]  
[Anonymous], 2005, PHARMACOPOEIA PEOPLE
[2]  
[Anonymous], 2012, DISC STUD MOD ENV RE
[3]  
Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005
[4]  
Fernandez-Cruz E, 2008, Actas Dermosifiliogr, V99 Suppl 4, P2
[5]   STRUCTURE OF INTERLEUKIN 1-ALPHA AT 2.7-A RESOLUTION [J].
GRAVES, BJ ;
HATADA, MH ;
HENDRICKSON, WA ;
MILLER, JK ;
MADISON, VS ;
SATOW, Y .
BIOCHEMISTRY, 1990, 29 (11) :2679-2684
[6]   Small-molecule inhibition of TNF-α [J].
He, MM ;
Smith, AS ;
Oslob, JD ;
Flanagan, WM ;
Braisted, AC ;
Whitty, A ;
Cancilla, MT ;
Wang, J ;
Lugovskoy, AA ;
Yoburn, JC ;
Fung, AD ;
Farrington, G ;
Eldredge, JK ;
Day, ES ;
Cruz, LA ;
Cachero, TG ;
Miller, SK ;
Friedman, JE ;
Choong, IC ;
Cunningham, BC .
SCIENCE, 2005, 310 (5750) :1022-1025
[7]   Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy - A randomized, placebo-controlled, 52-week trial [J].
Keystone, EC ;
Kavanaugh, AF ;
Sharp, JT ;
Tannenbaum, H ;
Hua, Y ;
Teoh, LS ;
Fischkoff, SA ;
Chartash, EK .
ARTHRITIS AND RHEUMATISM, 2004, 50 (05) :1400-1411
[8]   Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial [J].
Klareskog, L ;
van der Heijde, D ;
de Jager, JP ;
Gough, A ;
Kalden, J ;
Malaise, M ;
Mola, EM ;
Pavelka, K ;
Sany, J ;
Settas, L ;
Wajdula, J ;
Pedersen, R ;
Fatenejad, S ;
Sanda, M .
LANCET, 2004, 363 (9410) :675-681
[9]  
Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO
[10]  
2-V